Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07690761 Zanubrutinib Hairy Cell Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07690761 clinical trial report covering Zanubrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127842 Budesonide Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600127842 clinical trial report covering Budesonide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07702474 Chitosan Recurrent aphthous ulcer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07702474 clinical trial report covering Chitosan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07550231 AD-211 Osteoarthritis, Knee Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07550231 clinical trial report covering AD-211, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
8 min read
Autologous CIK Cells(Siriraj Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Autologous CIK Cells(Siriraj Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CD19/CD22 CAR-T (Essen Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
CD19/CD22 CAR-T (Essen Biotech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EB-NK-301 (Beijing Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
EB-NK-301 (Beijing Biotech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PepGNP-SARSCoV2 (Emergex Vaccines) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
PepGNP-SARSCoV2 (Emergex Vaccines): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Anti-CD30 CAR T-cell therapy(Bio-Raid) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Anti-CD30 CAR T-cell therapy(Bio-Raid): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Secretome(Baermed) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Secretome(Baermed): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
JY-231 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
JY-231: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TolDCB29 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
TolDCB29: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.